Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition containing ginsenoside Rg3 and notoginsenoside ft1

A technology of Panax notoginseng saponins and ginsenosides, applied in the field of medicine, can solve the problems of less reports on the pharmacological activity of Panax notoginseng saponins, and achieve the effect of enhancing the immune response function of the body

Inactive Publication Date: 2016-08-10
瑞莱茵(北京)生物科技有限责任公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are few reports on the pharmacological activity of notoginseng saponin ft1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing ginsenoside Rg3 and notoginsenoside ft1
  • Composition containing ginsenoside Rg3 and notoginsenoside ft1
  • Composition containing ginsenoside Rg3 and notoginsenoside ft1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] The preparation of embodiment 1 ginsenoside Rg3 and notoginseng saponin ft1 injection

[0016] Weigh 58g of arginine and water of equal quality, stir evenly, add 125g of ginsenoside Rg3 and 150g of notoginsenoside ft1, heat to 50°C, stir to dissolve, adjust the pH value to 4.6 with an aqueous solution containing 9% hydrochloric acid, and add water to the full amount , stir evenly; then add activated carbon with a liquid dosage of 0.1% (g / ml), stir for 25 minutes, and decarbonize by coarse filtration; pass through a 0.22 μm filter membrane to obtain a fine filtrate; potting, 2 mL per bottle; 118 ° C Autoclaving for 18 minutes, inspection, packaging, and storage.

Embodiment 2

[0017] The preparation of embodiment 2 ginsenoside Rg3 and notoginseng saponin ft1 tablet

[0018] 1) Mix 20 g of ginsenoside Rg3 and 10 g of notoginsenoside ft1 and stir evenly to obtain a powdery solid;

[0019] 2) Mix the powder obtained in step (1) with 55g of lactose, 2.6g of sodium carboxymethyl starch and 4.3g of micropowdered silica gel, add 63g of arginine to make a suitable soft material, and granulate with a 20-mesh sieve;

[0020] 3) Mix 5.2 g of sodium carboxymethyl starch and 1.5 g of micropowdered silica gel with the dry granules obtained in step (2), and press into tablets to obtain tablets.

Embodiment 3

[0021] The preparation of embodiment 3 ginsenoside Rg3 and notoginseng saponin ft1 capsule

[0022] Weigh 20g of ginsenoside Rg3 and 20g of notoginsenoside ft1, add 274g of starch, mix well, sieve, use ethanol aqueous solution as binder to make a suitable soft material, granulate with 18 mesh sieve, and dry in an oven at 60°C for 5 hours. Sieve through a 16-mesh sieve, add 2g of magnesium stearate, and mix well to obtain capsules.

[0023] The application of the composition of the present invention in antitumor will be described below in conjunction with specific experiments.

[0024] Experimental animals: Kunming mice were purchased from the Experimental Animal Center of Kunming Medical College.

[0025] Cells: B16 melanoma cells (B16melanoma cell) and human hepatoma cell (HepG2) cells were purchased from American Type Cell Bank (ATCC, Hanassas, VA, USA).

[0026] Medium: DMEM (FBS; HyClone, Logan, UT, USA) for cell culture, supplemented with 10% fetal bovine serum (FBS; Hy...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition containing ginsenoside Rg3 and notoginsenoside ft1. The composition comprises, by weight, 30 to 70% of ginsenoside Rg3 and 0 to 70% of notoginsenoside ft1. The invention also discloses application of the composition to drugs used for preventing and treating cancers, anticancer ancillary drugs, and medicines or health products for improving immunity. The composition provided by the invention can inhibit tumor cells, stimulates propagation of lymphocytes and has excellent pharmacological effect and drug effect; and better security is obtained on the bases of conservation of resources and better drug effect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a composition containing ginsenoside Rg3 and notoginsenoside ft1. Background technique [0002] In my country, about 1.6 million people are newly diagnosed with cancer and about 1.3 million people die from cancer every year. The incidence of cancer in the world and in my country is increasing year by year. However, cancer patients in our country still account for the majority of advanced cancer patients when they see a doctor, and they have lost the chance of radical cure such as surgery and have poor treatment effects. According to the current level of cancer death in our country, two people die of cancer every minute in the whole country, and more than 2,800 people will be killed by cancer every day, which is equivalent to the destruction of a city with a population of one million in one year. It can be seen that cancer is a common and frequently-occurring diseas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00A61P37/04
CPCA61K31/704A61K2300/00
Inventor 沈勇罗杰邓毅
Owner 瑞莱茵(北京)生物科技有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com